John K. Cini

Dr. John Cini is Chief Scientific Officer and a Co-Founder of Sonnet BioTherapeutics, where he oversees and directs the company’s discovery and development programs. His role includes the oversight of the selection process of cancer and immune-oncology targets and proof-of-concept testing.

Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics. He has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization.

Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini’s therapeutic areas of expertise in system biology include oncology, immune-oncology, inflammation, osteoporosis, wound healing, surgical adhesion, and cellular aging.